Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis
- 1 September 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 13 (9), 1135-1140
- https://doi.org/10.1002/ibd.20165
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis PatientsThe American Journal of Gastroenterology, 2007
- Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel diseaseInflammatory Bowel Diseases, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Health-related Quality of Life in Patients with Inflammatory Bowel Disease Measured with the Short Form-36: Psychometric Assessments and a Comparison with General Population NormsInflammatory Bowel Diseases, 2005
- Impairment of Health-Related Quality of Life in Patients With Inflammatory Bowel Disease: a Spanish Multicenter StudyInflammatory Bowel Diseases, 2005
- Quality of life in patients with established inflammatory bowel disease: a UK general practice surveyAlimentary Pharmacology & Therapeutics, 2004
- Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut, 1993
- Tumour necrosis factor alpha in stool as a marker of intestinal inflammationThe Lancet, 1992
- Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.Gut, 1991
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987